The “ Ask Me Anything ” (AMA) event was hosted on the ALS News Today Forums. Our featured guest was James Smith ...
COYA 302, an injection therapy in development for the treatment of ALS, has been awarded fast track status by the U.S. Food and Drug Administration. The therapy aims to slow ALS progression by ...
The ALS Association is awarding $3 million in grants to expand access to specialized care in the U.S. The new funding targets underserved, geographically isolated communities lacking multidisciplinary ...
A cellular recycling system called CMA was found to be impaired in ALS motor neurons. Reduced CMA activity was linked to TDP-43 protein clumps, a hallmark of most ALS cases. Boosting CMA may be a ...
EverythingALS has launched a new online tool called SAVA AI that uses artificial intelligence to instantly match people with amyotrophic lateral sclerosis (ALS) to clinical trials.
Todd’s journey with ALS began when our children were only 9 months and 4 years old. Teaching them and preparing them for life has given us a sense of purpose in the midst of our personal pain. We’ve ...
Fast-track status is intended to speed the development and review of treatments for serious conditions with unmet medical needs. It will allow Spinogenix to have more frequent interactions with the ...
Acurastem has received $7.5 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance AS-241, its lead clinical candidate for amyotrophic lateral sclerosis (ALS) and ...
Au8, an experimental ALS therapy. CNM-Au8 has been associated with NfL reductions, a biomarker finding linked to longer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results